Compare Illumina, Inc. (ILMN) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nasdaq100 ETF — how do they compare? Illumina, Inc. trades at $189.99 (market cap $27.94B), while Nasdaq100 ETF trades at $705.97. The key difference: Illumina, Inc. is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | QQQ | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | — |
52-Week High | $194.33 | $746.16 |
52-Week Low | $91.00 | $553.88 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
QQQ trades at $696.06, up 0.1% on the day, with technical indicators showing a bearish trend amid neutral oscillators. The ETF faces mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights concentration in big tech and institutional position adjustments, while a future dividend of $0.81 is scheduled for July 2026.
Outlook remains cautious due to technical bearishness and divided analyst views. Key risks include tech sector volatility and macroeconomic factors influencing rate decisions. Upside potential hinges on sustained AI-driven growth, but investors should weigh concentration risks in Nasdaq-100 holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
